The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Tumor models for efficacy determination
Abstract
The first in vivo tumor models were developed in the mid-1960s. These models were mouse leukemia models grown as ascites. The growth pattern was like that of bacteria in vivo and therefore it was possible to apply similar mathematics of growth and response to these tumors as had been worked out for bacteria. Since the development of the murine leukemia models, investigators have devoted a large effort to modeling solid tumors in mice. There are now a variety of models including syngeneic mouse tumors and human tumor xenografts grown as s.c. nodules, syngeneic mouse tumors and human tumor xenografts grown in orthotopic sites, models of disseminated disease, “labeled” tumor models that can be visualized using varied technologies, and transgenic tumor models. Each of these types of models has advantages and disadvantages to the “drug hunter” searching for improved treatments. [Mol Cancer Ther 2006;5(10):2435–43]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Kelland, L. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.028 · Cited by 352
Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324
Cao, Y., Li, C.-Y., Moeller, B. J., Yu, D., Zhao, Y., Dreher, M. R., Shan, S., & Dewhirst, M. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4553 · Cited by 92
Cited by
The Smart Drug Delivery System and Its Clinical Potential
Liu, D., Yang, F., Xiong, F., & Gu, N. (2016) · Theranostics · doi:10.7150/thno.14858 · Cited by 1,066
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
Cancer treatments: Past, present, and future
Sonkin, D., Thomas, A., & Teicher, B. A. (2024) · Cancer Genetics · doi:10.1016/j.cancergen.2024.06.002 · Cited by 548
Self-citationSalunkhe, S., Dheeraj, Basak, M., Chitkara, D., & Mittal, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.042 · Cited by 497
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
Metadata
- Authors
- Teicher, B. A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-10-01
- Volume
- 5
- Issue
- 10
- Pages
- 2435-2443
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W1981723789
- Cited by
- 186
- References
- 4
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor models for efficacy determination. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0391
- The paper
- Teicher, B. A. (2006). Tumor models for efficacy determination. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.